This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.

Start Date01 Jul 2025

Sponsor / Collaborator

Thomas Jefferson University

[+3]

NCT06066723

/ RecruitingNot ApplicableIIT

A Cross-sectional Pilot Study of 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

This study capitalizes on the emerging technology of 19F MRI, using conventional 'thermally' polarized perfluorinated gas (perfluoropropane, or PFP) mixed with oxygen and studied with magnetic resonance imaging (MRI) to visualize ventilation. This technique has not been studied in children.
Children and adolescents (6-17 years old) with cystic fibrosis (CF) who have normal spirometry will undergo 19F MRI with the inhalation of an inert contrast gas to study ventilation. Comparisons will be made to a cohort of healthy children (6-17 years old) who will perform the same measures. The primary outcome measure is the feasibility of conducting these studies in the pediatric population. Parallel performance of multiple breath nitrogen washout (MBW) and spirometry will be used to compare the sensitivity of these outcomes to the presence of mild lung disease in these children. Finally, the investigators will compare data obtained during standard breath holds with a novel "free-breathing" technique that will eliminate the need for breath holds during MRI acquisition.

Start Date23 Jun 2025

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+2]

NCT06797193

/ RecruitingNot ApplicableIIT

Invoking Subharmonics and Subharmonic Aided Pressure Estimation (SHAPE) for Identifying Portal Hypertension

This clinical trial tests the how well an ultrasound with subharmonic imaging and the subharmonic aided pressure estimation (SHAPE) technique works in identifying portal hypertension (PH). An ultrasound takes pictures of the inside of the body by bouncing sound waves off organs. PH is high blood pressure in the vein that carries blood to the liver from the stomach, small and large intestines, spleen, pancreas, and gallbladder. The complications associated with PH are clear only after severe liver dysfunction or liver cirrhosis develops and are accompanied by relatively high mortality rates (20-70% mortality within 2 years). Thus, identifying PH earlier is beneficial. The hepatic venous pressure gradient (HVPG) obtained using an invasive catheterization procedure remains the standard for assessing PH. However, using this invasive procedure to assess PH prevents frequent pressure monitoring. Thus, a noninvasive technique to estimate PH is beneficial not only for diagnosis but also for monitoring treatment and disease progression. The SHAPE technique is a noninvasive ultrasound-based imaging technique that can estimate pressure with an ultrasound contrast agent. A noninvasive technique using an ultrasound with subharmonic imaging and the SHAPE technique may work in identifying PH.

Start Date13 Mar 2025

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Perflutren lipid microsphere

100 Translational Medicine associated with Perflutren lipid microsphere

100 Patents (Medical) associated with Perflutren lipid microsphere

2,319

Literatures (Medical) associated with Perflutren lipid microsphere

01 Jul 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Colour Doppler and Contrast-Enhanced Ultrasound Characteristics in Degenerative Retinoschisis and Retinal Detachment

Article

Author: Macri, Carmelo ; LE, Matthew ; Gun, Meegan ; Sammouh, Fady ; Lee, Yong Min ; Chan, Weng Onn ; Paris, Jai ; Lim, Wanyin

PURPOSE:

To investigate and compare the characteristics of colour Doppler ultrasound (CDUS) and contrast-enhanced ultrasound (CEUS) in degenerative retinoschisis (RS) and rhegmatogenous retinal detachment (RD).

DESIGN:

Prospective, observational case series.

METHODS:

We prospectively enrolled patients with degenerative RS, acute RD, or chronic RD at two tertiary centres from January 2024 to January 2025. Patients underwent clinical examination, ultrawide field photography and optical coherence tomography (OCT), and CDUS, followed by CEUS with Definity® microbubbles. Ultrasound characteristics between groups were compared.

RESULTS:

We included 65 eyes from 47 patients (25 male, median age 61.8). There were 51 eyes with RS, 6 eyes with acute RD, and 6 eyes with chronic RD. CDUS revealed no pre-contrast doppler flow in any RS, while all acute RD cases demonstrated doppler flow. CEUS displayed mild microbubble uptake in 18 RS cases (median bubble count of 2), whereas all RD cases exhibited florid uptake (median bubble count of 48.2). Compared to RS, acute RD cavities had significantly higher elevation from sclera (by 6.0 CI 2.8-9.2 mm), longer cavity lengths (by 9.8 CI 7.2-12.5), and greater membrane thickness (by 0.89 CI 0.6-1.2 mm). Chronic RD were significantly thicker than RS membranes (by 0.40 CI 0.2-0.6 mm) but were no longer or with greater elevation. Pixelated image analysis showed compared to RS, acute RD showed a higher average total particle count (by 45.83 units), larger particle size (by 66.3 pixels), and greater total particle area (by 3138 pixels). Chronic RD cases had mixed CDUS and CEUS findings.

CONCLUSIONS:

CDUS features differentiating between degenerative RS and RD included the lack of doppler flow in RS, higher and longer cavities in acute RD, and thicker membranes in acute and chronic RD. CEUS features differentiating RS and RD included florid microbubble contrast enhancement in acute RD. These findings could aid in the investigation of cases with diagnostic uncertainty.

01 Jun 2025·FLUID PHASE EQUILIBRIA

Accurate calculation and reliable prediction of second virial coefficients for nonpolar mixtures

Author: Qin, Kang ; Xu, Liu ; Duan, Yuan-Yuan

The virial equation of state has a theor. advantage in the calculations of mixturesThe second mixture virial coefficients are with the theor. rigid mixing rules and composed of the second virial coefficients for pure fluids and the cross second virial coefficientsBased on the generalized corresponding state principle second virial coefficient model for pure fluids we proposed before, the generalized cross second virial coefficient models were established with three characteristic parameters for nonpolar binaries in this work.The calculation of the mixture critical temperature requires the binary interaction coefficients (k_ij).The mixture acentric factor was determined by the arithmetic mean.The mixture critical pressure could be calculated without the critical sp. volumeFor the most sensitive mixing rule of the mixture critical temperature, the k_ij was optimized for 145 nonpolar binaries.An easily accessible characteristic correlating parameter, the reduced diameter, was proposed to develop the predictive k_ij correlations for common nonpolar binaries.Due to the complex intermol. interactions between two different mols., the k_ij correlations were proposed resp. for alkane/alkane binaries, nonpolar binaries containing fluorocarbon, nonpolar binaries containing nitrogen or oxygen, nonpolar binaries containing simple fluids, nonpolar binaries containing carbon dioxide and nonpolar binaries containing neon.Our work was validated to perform satisfactorily from the comparison with the Chueh-Prausnitz k_ij correlation, Fender-Halsey k_ij correlation, and Meng k_ij correlation.Together with our previous work, this work could accurately calculate and reliably predict the second virial coefficients for common nonpolar mixtures

01 Jun 2025·Computational and Theoretical Chemistry

Electron and positron impact ionization cross sections of neutral molecular species dissociating from C4F7N and its mixtures

Author: Geetha, D. ; Gupta, Dhanoj

The electron and positron impact ionization cross sections are reported for neutral fragments originating from C4F7N and their mixture with air, CO₂, and N₂ using the Binary-Encounter Bethe (BEB) method and its variants, such as BEB-W and BEB-B.The neutral targets studied are HF, CO, CO₂, COF₂, CHF₃, CF₃, CF₄, C2F₄, C₂F₆, C₃F₆, C₃F₈, C₄F₆, C₄F₈, C₄F₁₀, CN, HCN, CFN, C₂N₂, C₂FN, C₂F₃N, C₃F₃N, C₃F₄N, C₃F₅N mols.The results for most of the targets for electron imapct ionization compare well with the available exptl. and theor. results.However, for most of the mols., the estimates of positron impact ionization are the first attempt.The correlation of the maximum ionization cross section for both electrons and positrons with the polarizability and the number of electrons of the target gave a good correlation fit.The cross section data presented in this article are important for C₄F₇N plasma.

News (Medical) associated with Perflutren lipid microsphere

22 Jul 2022

·www.sciencedaily.com

Porous crystals bind fluorine-containing greenhouse gases

Fluorine-containing gases -- including so-called per- or polyfluorinated hydrocarbons, or PFCs -- have a significant share in global warming. Researchers recently developed new crystalline materials that can selectively adsorb the molecules of such carbon-fluorine bonds. They hope that these porous crystals may be useful for targeted binding and recovery of PFCs. Emissions of greenhouse gases contribute significantly to global warming. Not only carbon dioxide (CO2) but also fluorine-containing gases -- including so-called per- or polyfluorinated hydrocarbons, or PFCs -- have a significant share in this development. Researchers at the Institute of Organic Chemistry of Heidelberg University led by Prof. Dr Michael Mastalerz recently developed new crystalline materials that can selectively adsorb the molecules of such carbon-fluorine bonds. The Heidelberg researchers hope that these porous crystals may be useful for targeted binding and recovery of PFCs. Polyfluorinated carbons are organic compounds of various lengths in which the hydrogen atoms of alkanes are partly or fully replaced by fluorine atoms. These atoms are chemically highly stable. They are not ubiquitous in nature and are used mainly for etching processes in the semiconductor industry, in eye surgery, and in medical diagnostics as contrast enhancers for certain ultrasound examinations. "Unlike CO2, which is integrated in natural material cycles, PFCs accumulate in the atmosphere and stay there for several thousands of years before breaking down," stresses Prof. Mastalerz. Compared to carbon dioxide, PFCs thus have a much greater global warming potential -- the impact of one PFC molecule is virtually equal to 5,000 to 10,000 CO2 molecules. According to the researcher, that makes polyfluorinated hydrocarbons a permanent problem that is not only contributing to global warming now but accelerating it as well. With his research group at the Institute of Organic Chemistry of Heidelberg University, Prof. Mastalerz has developed a new type of crystalline material that can adsorb polyfluorinated hydrocarbons highly selectively, i.e., binding them to its interior surface. The porous crystals are based on shape-persistent organic cage compounds that carry fluorine-containing side chains on the interconnected struts. These side chains react according to the "like attracts like" principle via fluorine-fluorine interactions with the PFC molecules, ensuring they are deposited on the inner surface of the material. In their experiments, the Heidelberg researchers proved that the crystals they developed bind certain fluorine-containing gases such as octafluoropropane or octafluorocyclobutane approximately 1,500 to 4,000 times more strongly than dinitrogen, the main component of air. According to Prof. Mastalerz, these numbers represent extraordinarily high selectivities to bind such PFCs. Currently Prof. Mastalerz and his team are working on further increasing the selectivity of the crystals and transferring the process to other fluorinated gases, such as those used in medical anaesthesia. "I see enormous potential for development in this area," emphasises the researcher. He hopes that the adsorbent can be used for recovery of polyfluorinated hydrocarbons at their point of use. The German Research Foundation funded the research.

27 May 2021

·www.biospace.com

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U.S. by year end NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only commercially available approved PSMA PET imaging agent for prostate cancer. The product will be immediately available in parts of the mid-Atlantic and southern regions and availability is expected to rapidly expand over the next six months with broad availability across the U.S. anticipated by year end. “The FDA approval of PYLARIFY is a significant milestone for Lantheus and the prostate cancer community in the United States. We believe PYLARIFY represents a paradigm shift in the identification and management of patients with suspected metastasis or recurrent prostate cancer, providing more accurate and earlier detection of disease than conventional imaging so that doctors, along with patients and their families, can make more informed treatment decisions,” said Mary Anne Heino, President and Chief Executive Officer of Lantheus. “I would like to thank the patients who participated in our clinical trials, the study investigators and our employees, whose efforts made this achievement possible.” Identification of suspected metastatic disease in men considering initial definitive therapy is important to optimize treatment planning and to avoid futile interventions. Of men with localized prostate cancer who undergo initial curative intent/management, up to 50% may experience recurrence of their disease within ten years of treatment.1 Recurrent disease is often detected by a rise in serum prostate-specific antigen (PSA) levels; however, conventional imaging, especially at low PSA levels, is not able to identify the location and extent of the disease in the majority of cases.2,3 PYLARIFY was developed to target PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells.4 PYLARIFY binds to the target, enabling the reader of the PET scan to detect and locate the disease. Cyclotron production of F 18 offers high batch capacity and high image resolution, and F 18’s 110-minute half-life allows for wide geographic distribution.5,6 “Conventional imaging has significant limitations in detecting prostate cancer, both in initial staging and when the cancer has recurred or spread after initial primary treatment. Specifically, standard imaging poorly detects the early spread to distant organs, such as the lymph nodes, bones, and other organs,” said Michael J. Morris, M.D., Prostate Cancer Section Head, Genitourinary Medical Oncology, Memorial Sloan Kettering Cancer Center and the Lead Study Investigator in the CONDOR trial and Study Investigator in the OSPREY trial. “PYLARIFY can detect the spread of disease well before standard imaging and can be a transformative diagnostic tool that helps clinicians develop treatment plans based on a much more accurate understanding of a patient’s distribution of disease.” “We believe today’s approval is a game-changer for men facing prostate cancer," said Jamie Bearse, Chief Executive Officer of ZERO - The End of Prostate Cancer, a Patient Advocacy Group. "Having a diagnostic tool that allows doctors to see suspected metastatic or recurrent prostate cancer earlier, anywhere in the body, is a significant step forward and will have a tremendous impact on patients' lives.” The approval of PYLARIFY is based on data from two Company-sponsored pivotal studies (OSPREY and CONDOR) designed to establish the safety and diagnostic performance of PYLARIFY across the prostate cancer disease continuum. Results from OSPREY (Cohort A) demonstrated improvement in specificity and positive predictive value (PPV) of PYLARIFY PET imaging over conventional imaging in men at risk for metastatic prostate cancer prior to initial therapy. CONDOR studied men with biochemical recurrent prostate cancer. In patients with biochemical recurrent prostate cancer and non-informative baseline imaging, PYLARIFY demonstrated high correct localization and detection rates, including in patients with low PSA values (median PSA 0.8 ng/mL). In the clinical trials, PYLARIFY was well tolerated. In OSPREY and CONDOR, 593 patients with various states of prostate cancer were exposed to a single dose of PYLARIFY. Adverse reactions (headache, dysgeusia and fatigue) were reported in ≤ 2% of patients within the studies. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reaction. About PYLARIFY® PYLARIFY® (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. For men with prostate cancer, PYLARIFY PET combines the accuracy of PET imaging2, the precision of PSMA targeting and the clarity of an F 18 radioisotope5 for superior diagnostic performance. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection.1,5,7,8,9 About Prostate Cancer Prostate cancer is the second most common form of cancer affecting men in the United States -- an estimated one in eight men will be diagnosed with prostate cancer in their lifetimes. The American Cancer Society estimates that in 2021, almost 250,000 new cases of prostate cancer will be diagnosed, and more than 30,000 men will die of the disease. Approximately 3.1 million men in the United States currently count themselves as prostate cancer survivors.10 PYLARIFY® (piflufolastat F 18) Injection Indication PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Important Safety Information Contraindications None. Warnings and Precautions Risk of Image Misinterpretation Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Hypersensitivity Reactions Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available. Radiation Risks Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. Adverse Reactions The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies with PYLARIFY. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions. Drug interactions Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established. To report suspected adverse reactions for PYLARIFY, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or . For important risk and use information about PYLARIFY Injection, please see Full Prescribing information. About Lantheus Holdings, Inc. Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit . Safe Harbor for Forward-Looking and Cautionary Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “anticipate,” “believe,” “confident,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) a delay in obtaining, or failure to obtain, FDA approval for additional PET manufacturing facilities that will manufacture PYLARIFY; (ii) the Company’s ability to successfully launch PYLARIFY as a commercial product; (iii) the ability of the Company’s third party PET manufacturing facilities and radiopharmacies to supply PYLARIFY to the market; (iv) the market receptivity to PYLARIFY as a new diagnostic agent; (v) the safety and efficacy of PYLARIFY; (vi) the intellectual property protection of PYLARIFY; and (vii) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q). 1Mena et al. 18 F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy J Nucl Med 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799. Epub 2019 Nov 1. 2Alipour et al. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019; 11: 1758835919876828. 3Taneja Imaging in the Diagnosis and Management of Prostate Cancer Rev Urol. 2004 Summer; 6(3): 101–113. 4Ceci & Fanti. PSMA-PET/CT imaging in prostate cancer: why and when. Clinical and Translational Imaging volume 7, pages 377–379 (2019). 5Werner et al 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging Theranostics 2020; 10(1):1-16. doi:10.7150/thno.37894. 6Martiniova et al. Gallium-68 in Medical Imaging Curr Radiopharm 2016;9(3):187-207. doi: 10.2174/1874471009666161028150654. 7Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20(1):1-8. doi:10.1186/s40644-020-0290- 8Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. doi:10.1148/radiol.2020191689 9PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company 10American Cancer Society. Facts & Figures 2021. American Cancer Society. Atlanta, GA. 2021. View source version on businesswire.com:

Diagnostic ReagentsSmall molecular drugCollaborate

01 Apr 2021

·www.biospace.com

Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel

April 1, 2021 12:30 UTC Names Daniel Niedzwiecki as Senior Vice President and General Counsel NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021 after more than 13 years with Lantheus. Mr. Duffy will be retained in an advisory capacity. His responsibilities will be assumed by Daniel Niedzwiecki, who has been with the Company since 2013 and will report directly to Mary Anne Heino, President and CEO. “On behalf of the entire Lantheus team and Board of Directors, I thank Mike for his many years of dedicated service to Lantheus and the radiopharmaceutical industry,” said Mary Anne Heino, President and Chief Executive Officer. “Mike is the consummate professional, a trusted advisor, a good friend, and it has been my absolute privilege to have worked with him. We wish Mike all the very best as he embarks on new adventures in his retirement.” “I am honored and privileged to have been part of the team that, starting in 2008, transformed a private equity-backed carve-out from Bristol Myers Squibb into a free-standing public company with a growing product portfolio and pipeline, and a market cap that has expanded by more than seven times since the Company’s IPO in 2015,” said Mr. Duffy. “With the integration of last year’s acquisition of Progenics well advanced, now is an appropriate time for me to step back to pursue other interests. Dan has been an integral member of our strong legal team since 2013, and I believe he is the right leader to continue to help drive the business forward and create additional value for our stakeholders.” About Lantheus Holdings, Inc. Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit .

AcquisitionCollaborateIPO

100 Deals associated with Perflutren lipid microsphere

External Link

KEGG	Wiki	ATC	Drug Bank
D01738	Perflutren lipid microsphere	V08DA04	DB00556

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	15 Nov 2022
Contrast agents	United States	Lantheus Medical Imaging, Inc.	31 Jul 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Exertional Compartment Syndrome	Phase 3	United States	Lantheus Medical Imaging, Inc.	01 Jul 2020
Kidney Diseases	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	10 Nov 2017
Kidney Diseases	Phase 3	China	Lantheus Medical Imaging, Inc.	10 Nov 2017
Renal Cell Carcinoma	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	10 Nov 2017
Renal Cell Carcinoma	Phase 3	China	Lantheus Medical Imaging, Inc.	10 Nov 2017
Liver Diseases	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	21 Sep 2017
Liver Diseases	Phase 3	China	Lantheus Medical Imaging, Inc.	21 Sep 2017
Hepatocellular Carcinoma	Phase 3	United States	Lantheus Medical Imaging, Inc.	01 Apr 2016
Heart Failure	Phase 2	United States	Lantheus Medical Imaging, Inc.	01 Jun 2017
Adnexal Diseases	Phase 1	United States	Lantheus Medical Imaging, Inc.	01 Aug 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04185246 (CTgov)	Phase 1/2	Heart Defects, Congenital \| Heart Diseases	36	NH002 (Cohort 1)	dclqubaeif(qroqciwinc) = uhrvudfise uqmfizjopf (emodctyqhj, 19.37) View more	-	20 Dec 2024
				NH002 (Cohort 2)	dclqubaeif(qroqciwinc) = ddprasuvvr uqmfizjopf (emodctyqhj, 24.07) View more
NCT01835067 (Pubmed \| JAMA Ophthalmol)	Phase 2/3	Age Related Macular Degeneration	56	Intravitreal Tissue Plasminogen Activator (TPA)	swrmzmovba(iuvgwjomof) = pvvumqkayf ihijudpfbc (brsuxvsukc )	Positive	01 Dec 2024
				Perfluoropropane (C3F8)	swrmzmovba(iuvgwjomof) = qdrbbexwpk ihijudpfbc (brsuxvsukc )
NCT01835067 (TAPAS, EURETINA2024)	Phase 2/3	Age Related Macular Degeneration	56	C3F8	wmizrnuhqn(xasefxucvk) = gublqhhwaz ftqdziigkq (pjahkxrjkq )	Positive	19 Sep 2024
				TPA	wmizrnuhqn(xasefxucvk) = jnibeszuse ftqdziigkq (pjahkxrjkq )
NCT04118764 (CTgov)	Not Applicable	Alzheimer Disease	6	Neuronavigation-guided single-element focused ultrasound transducer+Amyvid+Definity	evkhccvxua = mwzbzygcuo wvrttxryhn (qvrhipwbyb, vcfzzaogrc - jbhoqiknhu) View more	-	26 Aug 2024
CTR20171087 (Pubmed \| BMC Pharmacol Toxicol)	Phase 1	-	-	perflutren lipid microsphere injection (DEFINITY®) (Male subjects)	mzemqifchv(zymwgennsk) = sjuloonasr blttbhirjo (prvwvzeixq ) View more	-	02 Jan 2024
				perflutren lipid microsphere injection (DEFINITY®) (Female subjects)	mzemqifchv(zymwgennsk) = ngqfoiktjj blttbhirjo (prvwvzeixq ) View more
NCT02764801 (CTgov)	Phase 3	Hepatocellular Carcinoma	131	Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound)	hdyndbrkgt = cyvmcntagc exreeuwekh (wblqsopnja, mwwprqwuzd - buyudmevac) View more	-	21 Sep 2023
ESC2023	Not Applicable	ST Elevation Myocardial Infarction	100	Sonothrombolysis with microbolus administration of perfluoropropane	faotddoyic(wwlscvivxk) = yygigfayae uoojyqcpoo (lllpreffrd )	-	25 Aug 2023
				Control group	faotddoyic(wwlscvivxk) = iekkeocohj uoojyqcpoo (lllpreffrd )
NCT03544268 (CTgov)	Phase 4	-	20	Acoustic Angiography+Definity (Acoustic Angiography)	tsfoticftm(urosanumdf) = wqyaskdhmm einfocebgq (pfmjxqiktp, aqdjlbqswr - hcekdkgqnp) View more	-	01 Apr 2022
				Acoustic Angiography+Definity (Image Optimization)	tsfoticftm(urosanumdf) = auztizlcvv einfocebgq (pfmjxqiktp, etiqufeexu - mcwapscttg) View more
ESC2020	Not Applicable	-	100	Perfluoropropane contrast	phjwpuxjzn(usiurbyosi) = vizxgrepch cfelerwsku (tiixyomnvw ) View more	-	29 Aug 2020
				Sulphur hexafluoride contrast	phjwpuxjzn(usiurbyosi) = arkzmokusx cfelerwsku (tiixyomnvw ) View more
NCT03297112 (CTgov)	Early Phase 1	Adnexal Diseases	12	Contrast-Enhanced Subharmonic Ultrasound Imaging+Perflutren Lipid Microspheres	vxnsekiwjz = lbmdnxggoz goaalzzvjm (ilbtvmgpfv, rbwsyujfxf - ktvqqmhqlw) View more	-	25 Sep 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis